Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18641518 | 0.81 | ESR2 (0.35) | L3MBTL1KDM4EALOX12ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21273306 | 0.79 | LOXL2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL19975396 | 0.79 | LOXL2 (0.31) | — | |
| SCHEMBL19984729 | 0.73 | GFER (0.36) | L3MBTL1 | |
| SCHEMBL19984560 | 0.71 | ESR2 (0.32) | — | |
| SCHEMBL18641375 | 0.69 | HRH3 (0.36) | ALDH1A1 | |
| SCHEMBL18641383 | 0.69 | KDM4E (0.56) | L3MBTL1KDM4EALOX12ALDH1A1 | |
| SCHEMBL28457543 | 0.69 | KDM4E (0.39) | L3MBTL1KDM4EALOX12ALDH1A1 | |
| SCHEMBL628287 | 0.67 | GSK3B (0.37) | — | |
| SCHEMBL19975348 | 0.67 | MAPT (0.33) | L3MBTL1KDM4EALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | L3MBTL1 2994/4885KDM4E 2469/4885ALOX12 2540/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | L3MBTL1 2994/4885KDM4E 2469/4885ALOX12 2540/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | L3MBTL1 2994/4885KDM4E 2469/4885ALOX12 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.